Kundalić, Ana

Link to this page

http://farfar.pharmacy.bg.ac.rs/APP/faces/author.xhtml?author_id=09828054-da60-43bf-b772-456de3114fcb&item_offset=0&project_offset=0&sort_by=dc.date.issued
Authority KeyName Variants
09828054-da60-43bf-b772-456de3114fcb
  • Kundalić, Ana (1)
Projects

Author's Bibliography

Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine

Jovanović, Aleksandar; Kundalić, Ana; Miladinović, Bojana; Džodić, Predrag; Catić-Đorđević, Aleksandra; Krajnović, Dušanka; Tadić, Ivana

(Savez farmaceutskih udruženja Srbije, 2023) 

TY  - CONF
AU  - Jovanović, Aleksandar
AU  - Kundalić, Ana
AU  - Miladinović, Bojana
AU  - Džodić, Predrag
AU  - Catić-Đorđević, Aleksandra
AU  - Krajnović, Dušanka
AU  - Tadić, Ivana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5352
AB  - Kao jedan od najvećih javnozdravstvenih izazova diabetes mellitus predstavlja razlog
konstantnog unapređenja farmakoterapije (1). Savremena terapija diabetes mellitus-a može
promeniti tok bolesti, prevenirati komplikacije i doprineti uštedi u zdravstvu (2). Cilj rada bio je da
se analizira potrošnja antidijabetika u Srbiji, u periodu od 2012. do 2021. godine i usklađenost sa
preporukama Nacionalnog vodiča. Podaci o potrošnji antidijabetika prikupljeni su iz publikacija
Agencije za lekove i medicinska sredstva Srbije. Za svaki internacionalni nezaštićen naziv (INN),
praćena je potrošnja izražena u standardizovanoj jedinici - definisanoj dnevnoj dozi na 1000
stanovnika u danu (DDD/1000 stanovnika/dan). Najveća potrošnja antidijabetika tokom ispitivanog
perioda primećena je 2020. godine, dok je najniža bila 2012. godine. Potrošnja antidijabetika u 2021.
godini iznosila je 92,18 DDD/1000 stanovnika/dan što je za 23,73% više u odnosu na 2012. godinu.
Među ovom grupom lekova dominira upotreba oralnih antidijabetika koji se u proseku primenjuju
4,45 puta više u odnosu na insulin i analoge. Najzastupljeniji lekovi u ukupnoj potrošnji antidijabetika
do 2017. godine bili su sulfonamidi i derivati sulfonilureje kada su u proseku činili 43,39%. Nakon
2017. godine prvo mesto po potrošnji zauzima metformin, čiji udeo u ukupnoj potrošnji
antidijabetika dostiže 48,75% u 2021. godini. Potrošnja novih oralnih antidijabetika je veoma mala i
ne prelazi 0,1% ukupne potrošnje tokom ispitivanog perioda. Ipak najveći porast je primećen u
upotrebi inhibitora natrijum-glukoznog kotransportera 2 (SGLT2) (3,19 DDD/1000 stanovnika/dan
u 2021. godini nasuprot 0,001 DDD/1000 stanovnika/dan u 2015. godini). Rastući trend potrošnje
posebno je izražen kod metformina i SGLT2 inhibitora. Rezultati ukazuju na usklađenost primene
antidijabetika sa preporukama Nacionalnog vodiča.
AB  - As one of the biggest public health challenges, diabetes mellitus represents the reason for the
constant pharmacotherapy improvement (1). Modern therapy of diabetes mellitus can alter the
course of the disease, prevent complications, and contribute to healthcare savings (2). This study
aimed to analyze the consumption of antidiabetic drugs in the Republic of Serbia from 2012 to 2021
and compliance with the recommendations of the National Guide. The consumption of all registered
antidiabetic drugs was obtained from publications of the Medicines and Medical Devices Agency of
Serbia. For each International Nonproprietary Name (INN), consumption was monitored and
expressed in a standardized unit-defined daily dose per 1000 inhabitants per day (DDD/1000
inhabitants/day). During the study period, the highest consumption was observed in 2020, while the
lowest was in 2012. Antidiabetic drug consumption in 2021 amounted to 92.18 DDD/1000
inhabitants/day, which is 23.73% higher compared to 2012. The consumption of oral antidiabetics
was dominant, on average 4.45 times more than insulin and analogs. The most commonly used drugs
until 2017 in total antidiabetic consumption were sulfonylureas and sulfonylurea derivatives,
constituting an average of 43.39%. After 2017, metformin took the lead in consumption, reaching
48.75% of total antidiabetic consumption in 2021. New oral antidiabetic drugs do not exceed 0.1%
of the total consumption during the examined period. However, sodium-glucose cotransporter-2
(SGLT2) inhibitors (3.19 DDD/1000 inhabitants/day in 2021 compared to 0.001 DDD/1000
inhabitants/day in 2015) noted the most significant increase. The increasing consumption trend is
particularly pronounced for metformin and SGLT2 inhibitors. The results indicate compliance in the
use of antidiabetic drugs with the National Guide recommendations.
PB  - Savez farmaceutskih udruženja Srbije
C3  - Arhiv za farmaciju
T1  - Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine
T1  - Diabetes in Serbia: trends in antidiabetic drug consumption from 2012 to 2021
VL  - 73
IS  - Suppl. 4
SP  - S51
EP  - S52
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5352
ER  - 
@conference{
author = "Jovanović, Aleksandar and Kundalić, Ana and Miladinović, Bojana and Džodić, Predrag and Catić-Đorđević, Aleksandra and Krajnović, Dušanka and Tadić, Ivana",
year = "2023",
abstract = "Kao jedan od najvećih javnozdravstvenih izazova diabetes mellitus predstavlja razlog
konstantnog unapređenja farmakoterapije (1). Savremena terapija diabetes mellitus-a može
promeniti tok bolesti, prevenirati komplikacije i doprineti uštedi u zdravstvu (2). Cilj rada bio je da
se analizira potrošnja antidijabetika u Srbiji, u periodu od 2012. do 2021. godine i usklađenost sa
preporukama Nacionalnog vodiča. Podaci o potrošnji antidijabetika prikupljeni su iz publikacija
Agencije za lekove i medicinska sredstva Srbije. Za svaki internacionalni nezaštićen naziv (INN),
praćena je potrošnja izražena u standardizovanoj jedinici - definisanoj dnevnoj dozi na 1000
stanovnika u danu (DDD/1000 stanovnika/dan). Najveća potrošnja antidijabetika tokom ispitivanog
perioda primećena je 2020. godine, dok je najniža bila 2012. godine. Potrošnja antidijabetika u 2021.
godini iznosila je 92,18 DDD/1000 stanovnika/dan što je za 23,73% više u odnosu na 2012. godinu.
Među ovom grupom lekova dominira upotreba oralnih antidijabetika koji se u proseku primenjuju
4,45 puta više u odnosu na insulin i analoge. Najzastupljeniji lekovi u ukupnoj potrošnji antidijabetika
do 2017. godine bili su sulfonamidi i derivati sulfonilureje kada su u proseku činili 43,39%. Nakon
2017. godine prvo mesto po potrošnji zauzima metformin, čiji udeo u ukupnoj potrošnji
antidijabetika dostiže 48,75% u 2021. godini. Potrošnja novih oralnih antidijabetika je veoma mala i
ne prelazi 0,1% ukupne potrošnje tokom ispitivanog perioda. Ipak najveći porast je primećen u
upotrebi inhibitora natrijum-glukoznog kotransportera 2 (SGLT2) (3,19 DDD/1000 stanovnika/dan
u 2021. godini nasuprot 0,001 DDD/1000 stanovnika/dan u 2015. godini). Rastući trend potrošnje
posebno je izražen kod metformina i SGLT2 inhibitora. Rezultati ukazuju na usklađenost primene
antidijabetika sa preporukama Nacionalnog vodiča., As one of the biggest public health challenges, diabetes mellitus represents the reason for the
constant pharmacotherapy improvement (1). Modern therapy of diabetes mellitus can alter the
course of the disease, prevent complications, and contribute to healthcare savings (2). This study
aimed to analyze the consumption of antidiabetic drugs in the Republic of Serbia from 2012 to 2021
and compliance with the recommendations of the National Guide. The consumption of all registered
antidiabetic drugs was obtained from publications of the Medicines and Medical Devices Agency of
Serbia. For each International Nonproprietary Name (INN), consumption was monitored and
expressed in a standardized unit-defined daily dose per 1000 inhabitants per day (DDD/1000
inhabitants/day). During the study period, the highest consumption was observed in 2020, while the
lowest was in 2012. Antidiabetic drug consumption in 2021 amounted to 92.18 DDD/1000
inhabitants/day, which is 23.73% higher compared to 2012. The consumption of oral antidiabetics
was dominant, on average 4.45 times more than insulin and analogs. The most commonly used drugs
until 2017 in total antidiabetic consumption were sulfonylureas and sulfonylurea derivatives,
constituting an average of 43.39%. After 2017, metformin took the lead in consumption, reaching
48.75% of total antidiabetic consumption in 2021. New oral antidiabetic drugs do not exceed 0.1%
of the total consumption during the examined period. However, sodium-glucose cotransporter-2
(SGLT2) inhibitors (3.19 DDD/1000 inhabitants/day in 2021 compared to 0.001 DDD/1000
inhabitants/day in 2015) noted the most significant increase. The increasing consumption trend is
particularly pronounced for metformin and SGLT2 inhibitors. The results indicate compliance in the
use of antidiabetic drugs with the National Guide recommendations.",
publisher = "Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine, Diabetes in Serbia: trends in antidiabetic drug consumption from 2012 to 2021",
volume = "73",
number = "Suppl. 4",
pages = "S51-S52",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5352"
}
Jovanović, A., Kundalić, A., Miladinović, B., Džodić, P., Catić-Đorđević, A., Krajnović, D.,& Tadić, I.. (2023). Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije., 73(Suppl. 4), S51-S52.
https://hdl.handle.net/21.15107/rcub_farfar_5352
Jovanović A, Kundalić A, Miladinović B, Džodić P, Catić-Đorđević A, Krajnović D, Tadić I. Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine. in Arhiv za farmaciju. 2023;73(Suppl. 4):S51-S52.
https://hdl.handle.net/21.15107/rcub_farfar_5352 .
Jovanović, Aleksandar, Kundalić, Ana, Miladinović, Bojana, Džodić, Predrag, Catić-Đorđević, Aleksandra, Krajnović, Dušanka, Tadić, Ivana, "Dijabetes u Srbiji: trendovi u potrošnji antidijabetika od 2012. do 2021. godine" in Arhiv za farmaciju, 73, no. Suppl. 4 (2023):S51-S52,
https://hdl.handle.net/21.15107/rcub_farfar_5352 .